#Denmark #biotechnology #Water Filtration #Kongens Lyngby #Aquaporin A/S

Aquaporin A/S Holds Extraordinary General Meeting

On December 1, 2025, Aquaporin A/S, a trailblazer in water technology, held an extraordinary general meeting in Kongens Lyngby, Denmark, to discuss pivotal amendments to its Articles of Association that play a crucial role in the company’s growth strategy.

Key Outcomes of the Meeting

The general meeting focused on several significant proposals concerning the adjustment of the company’s share capital, which received enthusiastic approval from the shareholders. Notably, all proposals garnered over 99% of the votes cast.

1. Increase in Share Capital with Pre-emptive Rights

The first aspect approved involves the authorization for the Board of Directors to expand the company's share capital by a nominal amount of DKK 175,000,000. This increase is slated to be utilized within the time frame leading up to June 30, 2026, ensuring existing shareholders maintain their rights with the option of purchasing shares at a price that could fall below the market rate.

2. Increase in Share Capital without Pre-emptive Rights

Additionally, the Board was empowered to raise the same amount of DKK 175,000,000 in a manner that does not offer pre-emptive rights to current shareholders but requires that the share issuance occurs at or above the market price. This could facilitate quicker capital accumulation without the need for existing shareholders to exercise their purchase rights.

3. Capital Increase Benefiting Non-Shareholders

Another approved proposal allows for capital increase by the same nominal amount of DKK 175,000,000 without offering pre-emptive rights. This capital raise can benefit individuals outside the current shareholders—like employees or strategic partners—thereby attracting new investments and talent into the company.

4. Combined Limit for Authorizations

Lastly, a unified maximum of DKK 175,000,000 was established for the previously mentioned authorizations to simplify future financial maneuvers and ensure expedient capital management.

Commitment to Innovative Water Solutions

Aquaporin A/S maintains its core mission to address global water challenges through biotechnology. By utilizing its innovative Aquaporin Inside® technology—deriving from Nobel Prize-winning research—Aquaporin is at the forefront of rethinking water filtration. Their technology finds applications in industrial water treatment, enhancing the quality of drinking water, and even extending into space-related projects with organizations like NASA.

The authorization to manage share capital strategically positions Aquaporin for expanded growth and research initiatives, effectively facilitating partnerships that can further their mission of creating sustainable water solutions worldwide.

For those interested in understanding more about Aquaporin's agenda or the outcomes of the extraordinary general meeting, further details can be accessed through their investor relations channels or by contacting their CEO Ulrik Lund Jakobsen or CFO Klaus Juhl Wulff directly.

Conclusion

The extraordinary general meeting of Aquaporin A/S marks a crucial step in the company's journey towards transforming the water filtration landscape. With shareholders demonstrating robust support for these adjustments, Aquaporin is set to navigate the complexities of water issues more effectively and sustainably, ensuring a healthier future for communities globally.